Related Experiment Video

Updated: Sep 26, 2026

Characterization of Metabolic Status in Nonhuman Primates with the Intravenous Glucose Tolerance Test
06:59

Characterization of Metabolic Status in Nonhuman Primates with the Intravenous Glucose Tolerance Test

Published on: November 13, 2016

Prolonged hyperinsulinemic hypoglycemia in a small for date preterm

M Pezzati1, S Barni, G Chiti

  • 1Division of Neonatology, Department of Pediatrics, Azienda Ospedaliera Careggi, University of Firenze, Firenze, Italy.

Minerva Pediatrica
|March 28, 2003
PubMed

Insights

Prolonged hyperinsulinemic hypoglycemia in small-for-date preterm infants can be treated with glucose and diazoxide. This condition, a cause of infant hypoglycemia, may resolve spontaneously by two months of age.

Area of Science:

  • Neonatology
  • Pediatric Endocrinology
  • Metabolic Disorders

Background:

  • Hyperinsulinism is a significant cause of hypoglycemia in neonates.
  • Forms include transient, prolonged, and persistent hyperinsulinemic hypoglycemia.
  • Accurate diagnosis and treatment are crucial due to the risk of brain damage.

Observation:

  • A case of prolonged hyperinsulinemic hypoglycemia in a small-for-date preterm infant is presented.
  • Initial treatment involved high-dose glucose and glucocorticoids, followed by diazoxide.
  • Hypoglycemia persisted for two months.

Findings:

  • The infant's condition resolved spontaneously and completely at two months of age.
  • This suggests a potential self-limiting course for some prolonged hyperinsulinemic hypoglycemia cases.
  • Early and aggressive management may be key in preventing complications.

Implications:

  • This case highlights the importance of recognizing and managing prolonged hyperinsulinemic hypoglycemia in neonates.
  • It underscores the potential for spontaneous resolution in some cases, even with prolonged symptoms.
  • Further research into the natural history and optimal management strategies for this condition is warranted.

Related Concept Videos

Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
Hypoglycemia01:26

Hypoglycemia

Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Hyperglycemia01:29

Hyperglycemia

Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...
Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility, suggesting a...